Viewing StudyNCT04227028



Ignite Creation Date: 2024-05-06 @ 2:08 PM
Last Modification Date: 2024-10-26 @ 1:25 PM
Study NCT ID: NCT04227028
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-05-07
First Post: 2020-01-10

Brief Title: Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced Metastatic or Recurrent NSCLC
Sponsor: City of Hope Medical Center
Organization: City of Hope Medical Center

Conditions & Keywords Data

Conditions:
Name
Stage IVB Lung Cancer AJCC v8
Locally Advanced Lung Non-Small Cell Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Keywords: